Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Sanofi will leverage this partnership to provide access to proprietary data to develop AI models

Sanofi, Meningitis Research Foundation and CoMO launch awareness initiative on meningitis

Meningitis still affects more than 2.5 million people globally each year

Sanofi announces changes to its Executive Committee

Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.

Sanofi announces change in R&D leadership

Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim

Mandaviya urges stakeholders to partner with India to leverage opportunities at WEF Davos

India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries

Medicines, including insulin, to be available in 40 lower-income countries

Sanofi continues to deliver strong business

Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate